On November 14, 2016, news of an investigation an open-label Phase 2 clinical trial ("CONTROL") was revealed. The investigation concerned the incidence rate of severe diarrhea (grade 3) in early stage HER2+ breast cancer patients receiving Puma's Neratinib drug (the "incidence rate"). Following this high incidence of approximately 40%, the CONTROL study investigated the incidence rate where the antidiarrheal prophylaxis Loperamide was dispensed. The investigation showed a high incidence rate stayed at about 27% and that the CONTROL study was then extended to include a group of patients who were administered Loperamide and the corticosteroid Budesonide. The incidence rate did drop, but was still at a concerning 12.9%. Following this news, Puma stock dropped $10.30, or 20.43%, to close at $40.10 on November 14, 2016.
If you are aware of any facts relating to this investigation, or purchased Puma shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/pbyi. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
Logo - http://photos.prnewswire.com/prnh/20161114/439152LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-puma-biotechnology-inc-pbyi-300363518.html
SOURCE Bronstein, Gewirtz & Grossman, LLC